Brazikumab (MEDI2070 , initially known as AMG139) continues a significant therapeutic drug targeting the IL-17F cytokine. Emerging clinical data from the pivotal NYMPH3 trial evaluating its effectiveness in subjects with significant psoriaatic arthritis have revealed mixed findings. While early data demonstrated positive improvements in arthriti… Read More